Follow Healthline   |   Healthline on TwitterTwitter   |   Healthline on FacebookFacebook
Symptom Search   |   Treatment Search   |   Doctor Search   |   Drug Search

Drug Notebook

Generic Name: lamivudine

View All Brands
Epivir, Epivir HBV
An NRTI - It is used with other medicines to treat HIV
Search Drug Notebook
Hide
Your search results:
Search the lamivudine Drug Notebook
FDA Alerts

  • Lactic acidosis and severe hepatomegaly with steatosis (including some fatalities) reported rarely in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs) alone or in conjunction with other antiretrovirals. (See Lactic Acidosis and Severe Hepatomegaly with Steatosis under Cautions.)
  • Epivir® tablets and oral solution (used to treat HIV infection) contain a higher dose of lamivudine than Epivir-HBV® tablets and oral solution (used to treat hepatitis B virus). Patients with HIV should receive only the dosage forms appropriate for treatment of HIV.
  • HIV counseling and testing should be offered to all patients prior to and during Epivir-HBV® therapy. Epivir-HBV® tablets and oral solution contain a lower dose of lamivudine than Epivir® tablets and oral solution. Use of Epivir-HBV® in patients with unrecognized or untreated HIV infection may result in rapid emergence of resistant HIV because the dose is subtherapeutic and monotherapy is inappropriate.
  • Severe acute exacerbations of hepatitis B virus (HBV) reported following discontinuance of lamivudine in patients coinfected with HBV and HIV. Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months after lamivudine is discontinued in patients coinfected with HBV and HIV. If appropriate, initiation of treatment for HBV infection may be warranted.
  • The fixed-combination preparation Combivir® contains 2 NRTIs (lamivudine and zidovudine) the fixed-combination preparation Epzicom® contains 2 NRTIs (lamivudine and abacavir), and the fixed-combination preparation Trizivir® contains 3 NRTIs (abacavir, lamivudine, zidovudine); these are intended only for patients whose regimen would otherwise include lamivudine and the other components.
  • If using Combivir® or Trizivir®, consider that zidovudine has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in those with advanced HIV infection; and that prolonged zidovudine use has been associated with symptomatic myopathy.
  • If using Trizivir®, consider that data are limited regarding use of the fixed combination in patients with higher viral loads (>100,000 copies/mL) at baseline.

Media Gallery
Drug Info Tools
Search by color, shape and markings. click here
Check any 2 drugs for interactions. click here
Compare any two drugs side by side. click here
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
lamivudine
(la ME vyoo deen, 3TC)
GX CJ7 / GX CJ7 | 150 mgGX CJ7 / GX CJ7   150 mg
bottle, 60 each Lamivudine 150mg, Oral tablet, white, diamond-shaped, scored, side 1:GX CJ7, side 2:GX CJ7
GX EJ7 | 300 mgGX EJ7   300 mg
bottle, 30 each Lamivudine 300mg, Oral tablet, gray, diamond-shaped, side 1:GX EJ7
GX CG5 | 100 mgGX CG5   100 mg
bottle, 60 each Lamivudine 100mg, Oral tablet, yellow, biconvex, oblong-shaped, side 1:GX CG5
Back to Top